Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson

In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafenib plus Binimetinib.   Key topics included: Overview of the efficacy and survival data for both combinations Side effect profiles and management strategies Clinical pearls for oncologists in practice The importance of NGS testing in smokers and the role of targeted therapy versus chemoimmunotherapy Join us as we explore the latest insights and recommendations for managing these therapies, ensuring better patient outcomes and quality of life.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to check out our previous episodes for more on treatment algorithms and conference highlights! #BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers